Rankings
Pricing
Log In
Free Trial
US-listed companies
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc.
NVCT
Market cap
$108.39M
P/E ratio
Add to your list
Add to your list
Back to summarized table
B
M
K
USD
Annual
Quarterly
Download CSV
Income statement
Balance sheet
Cash flow
Dec 31,
2022
Dec 31,
2023
Net loss
-19
-22
Cost of share-based payments
2
5
Decrease/(increase) in other current assets
0
-0
Increase in accounts payable and accrued liabilities
4
-
(Decrease)/increase in accounts payable
-
-0
Net cash used in operating activities
-14
-16
(Decrease)/increase in accrued liabilities
-
-0
Increase in accrued compensation and benefits
-
1
Net cash used in operating activities
-14
-16
Private Placement
-
1
Proceeds from Issuance of Common Stock
-
5
Private Placement
-
1
Proceeds from Issuance of Common Stock
-
5
Initial Public Offering
3
-
Private Placement
2
-
Issuance costs related to At-the-market offering
-
0
Proceeds from Issuance Initial Public Offering
16
-
Initial Public Offering
3
-
Private Placement
2
-
Issuance costs related to At-the-market offering
-
0
Issuance costs related to initial public offering
-
0
Proceeds from Issuance of Private Placement
16
-
Net cash provided by financing activities
28
15
Proceeds from Warrant Exercises
-
11
Issuance costs related to the exercise of warrants, and preferred investment option
-
0
Issuance costs related to private placement
-
1
Net cash provided by financing activities
28
15
(DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS
14
-1
Private Placement
-
1
Proceeds from Issuance of Common Stock
-
5
Private Placement
-
1
Proceeds from Issuance of Common Stock
-
5
Initial Public Offering
3
-
Private Placement
2
-
Issuance costs related to At-the-market offering
-
0
Proceeds from Issuance Initial Public Offering
16
-
Initial Public Offering
3
-
Private Placement
2
-
Issuance costs related to At-the-market offering
-
0
Issuance costs related to initial public offering
-
0
Proceeds from Issuance of Private Placement
16
-
Net cash provided by financing activities
28
15
Proceeds from Warrant Exercises
-
11
Issuance costs related to the exercise of warrants, and preferred investment option
-
0
Issuance costs related to private placement
-
1
Net cash provided by financing activities
28
15
(DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS
14
-1
Unpaid Deferred Offering Costs
0
-
Unpaid Deferred Offering Costs
0
-